ADC Therapeutics SA
ADCT3.465USD
-0.235-6.35%
Market hours （ET）Quotes delayed by 15 min
390.25MMarket Cap
LossP/E TTM
More Details of ADC Therapeutics SA Company
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
ADC Therapeutics SA Info
Ticker SymbolADCT
Company nameADC Therapeutics SA
IPO dateMay 15, 2020
CEOMallik (Ameet)
Number of employees263
Security typeOrdinary Share
Fiscal year-endMay 15
AddressBiopole
CityEPALINGES
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountrySwitzerland
Postal code1066
Phone41216530200
Websitehttps://adctherapeutics.com/
Ticker SymbolADCT
IPO dateMay 15, 2020
CEOMallik (Ameet)
Company Executives of ADC Therapeutics SA
Name
Name/Position
Position
Shareholding
Change
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
+1.60%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
1.31M
-15.07%
Mr. Mohamed Zaki, M.D., Ph.D.
Mr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
601.26K
-6.39%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
351.57K
-13.15%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
311.53K
-13.71%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Vice Chairman of the Board, Lead Independent Director
Non-Executive Vice Chairman of the Board, Lead Independent Director
180.50K
+26.54%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Independent Director
Non-Executive Independent Director
134.98K
+38.35%
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
99.40K
+38.06%
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Non-Executive Independent Director
Non-Executive Independent Director
55.26K
+98.35%
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Director
Director
40.00K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
+1.60%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
1.31M
-15.07%
Mr. Mohamed Zaki, M.D., Ph.D.
Mr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
601.26K
-6.39%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
351.57K
-13.15%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
311.53K
-13.71%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Vice Chairman of the Board, Lead Independent Director
Non-Executive Vice Chairman of the Board, Lead Independent Director
180.50K
+26.54%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Redmile Group, LLC
12.65%
HPWH TH AG
7.00%
Point72 Asset Management, L.P.
6.57%
Prosight Capital
6.03%
OrbiMed Advisors, LLC
4.77%
Other
62.99%
Shareholders
Shareholders
Proportion
Redmile Group, LLC
12.65%
HPWH TH AG
7.00%
Point72 Asset Management, L.P.
6.57%
Prosight Capital
6.03%
OrbiMed Advisors, LLC
4.77%
Other
62.99%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
21.83%
Hedge Fund
16.53%
Corporation
8.80%
Investment Advisor
8.55%
Research Firm
6.43%
Individual Investor
4.96%
Private Equity
4.77%
Bank and Trust
0.39%
Venture Capital
0.07%
Other
27.66%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
191
72.94M
63.83%
-1.48K
2025Q3
203
72.94M
76.75%
+266.41K
2025Q2
196
72.67M
64.60%
+13.50M
2025Q1
198
59.17M
80.56%
-20.65M
2024Q4
201
60.84M
78.41%
+1.63M
2024Q3
204
59.22M
80.70%
+2.20M
2024Q2
196
56.12M
64.88%
+18.35M
2024Q1
159
35.17M
75.47%
-27.30M
2023Q4
158
34.44M
76.49%
-6.23M
2023Q3
162
40.67M
76.05%
-5.62M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Redmile Group, LLC
15.67M
13.93%
--
--
Jun 30, 2025
HPWH TH AG
8.67M
7.71%
-1.12M
-11.42%
May 15, 2025
Point72 Asset Management, L.P.
7.76M
6.9%
+7.76M
--
Jun 30, 2025
Prosight Capital
10.47M
9.3%
+924.77K
+9.69%
Jun 30, 2025
OrbiMed Advisors, LLC
5.91M
5.25%
-61.10K
-1.02%
Jun 30, 2025
Oaktree Capital Management, L.P.
4.02M
3.57%
+4.02M
--
Apr 25, 2024
BlackRock Institutional Trust Company, N.A.
4.06M
3.6%
-442.92K
-9.85%
Jun 30, 2025
Morgan Stanley & Co. LLC
2.99M
2.66%
+33.76K
+1.14%
Jun 30, 2025
Nantahala Capital Management, LLC
2.27M
2.01%
+2.27M
--
Jun 30, 2025
Auven Therapeutics General LP
2.23M
1.98%
-4.10M
-64.75%
Apr 23, 2024
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.06%
SPDR S&P International Small Cap ETF
0.04%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Growth ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.06%
SPDR S&P International Small Cap ETF
Proportion0.04%
iShares Biotechnology ETF
Proportion0.03%
iShares Russell 2000 Growth ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Fidelity Enhanced Small Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of ADC Therapeutics SA?
The top five shareholders of ADC Therapeutics SA are:
Redmile Group, LLC holds 15.67M shares, accounting for 13.93% of the total shares.
HPWH TH AG holds 8.67M shares, accounting for 7.71% of the total shares.
Point72 Asset Management, L.P. holds 7.76M shares, accounting for 6.90% of the total shares.
Prosight Capital holds 10.47M shares, accounting for 9.30% of the total shares.
OrbiMed Advisors, LLC holds 5.91M shares, accounting for 5.25% of the total shares.
Redmile Group, LLC holds 15.67M shares, accounting for 13.93% of the total shares.
HPWH TH AG holds 8.67M shares, accounting for 7.71% of the total shares.
Point72 Asset Management, L.P. holds 7.76M shares, accounting for 6.90% of the total shares.
Prosight Capital holds 10.47M shares, accounting for 9.30% of the total shares.
OrbiMed Advisors, LLC holds 5.91M shares, accounting for 5.25% of the total shares.
What are the top three shareholder types of ADC Therapeutics SA?
The top three shareholder types of ADC Therapeutics SA are:
Redmile Group, LLC
HPWH TH AG
Point72 Asset Management, L.P.
Redmile Group, LLC
HPWH TH AG
Point72 Asset Management, L.P.
How many institutions hold shares of ADC Therapeutics SA (ADCT)?
As of 2025Q4, 191 institutions hold shares of ADC Therapeutics SA, with a combined market value of approximately 72.94M, accounting for 63.83% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -12.92%.
What is the biggest source of revenue for ADC Therapeutics SA?
In --, the -- business generated the highest revenue for ADC Therapeutics SA, amounting to -- and accounting for --% of total revenue.
